Inovio announces results of pre-clinical study of Lassa fever vaccine.
Inovio Pharmaceuticals announced results of a study in which a DNA vaccine provided 100% protection for non-human primates challenged with a lethal dose of the Lassa fever virus. These results were published in the most recent issue of Human Vaccines & Immunotherapeutics in an article entitled, "A DNA Vaccine Delivered by Dermal Electroporation Fully Protects Cynomolgus Macaques Against Lassa Fever," by Inovio researchers and U.S. Army collaborators. In the study, funded by a previously awarded $3.5M grant from the National Institute of Allergy and Infectious Diseases, the animals first received Inovio's DNA vaccine against Lassa hemorrhagic fever via intradermal administration with CELLECTRA delivery device. The animals were then challenged with a lethal dose of the Lassa virus. "All of the animals survived; in fact, none of the vaccinated animals displayed any signs of disease," the company stated.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Oct 24, 2017|
|Previous Article:||Treasury Market Outlook: bond yields are sharply higher.|
|Next Article:||Waddell & Reed cuts dividend to 25c from 46c, announces $250M buyback.|